MA31109B1 - Nouveaux derives d'aminopyrimidine servant d'inhibiteurs de la plk1. - Google Patents

Nouveaux derives d'aminopyrimidine servant d'inhibiteurs de la plk1.

Info

Publication number
MA31109B1
MA31109B1 MA32115A MA32115A MA31109B1 MA 31109 B1 MA31109 B1 MA 31109B1 MA 32115 A MA32115 A MA 32115A MA 32115 A MA32115 A MA 32115A MA 31109 B1 MA31109 B1 MA 31109B1
Authority
MA
Morocco
Prior art keywords
group
cyclo
alkyl
alkoxy
optionally substituted
Prior art date
Application number
MA32115A
Other languages
Arabic (ar)
English (en)
Inventor
Takashi Hashihayata
Mikako Kawamura
Morihiro Mitsuya
Yoshiyuki Satoh
Original Assignee
Banyu Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Banyu Pharma Co Ltd filed Critical Banyu Pharma Co Ltd
Publication of MA31109B1 publication Critical patent/MA31109B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La présente invention concerne un composé de formule générale (i) : (i) dans laquelle ar1 représente un groupe formé à partir d'un cycle aromatique choisi dans un groupe comprenant un indole, un 1h-indazole, un 2h-indazole, un 1h-thiéno[2,3-c]pyrazole, un 1h-pyrazolo[3,4-b]pyridine, un benzo[b]furanne, un benzimidazole, un benzoxazole, un 1,2-benzisoxazole et un imidazo[1,2-a]pyridine ; r1 et r2 représentent chacun un atome d'hydrogène, un atome d'halogène, un groupe cyano, un groupe alkényle en c2-c6, un groupe alcoxy en c1-c6, un groupe halo-alcoxy en c1-c6, un groupe cyclo-alkyloxy en c3-c6, un groupe alcanoyle en c2-c7, un groupe halo-alcanoyle en c2-c7, un groupe alcoxycarbonyle en c2-c7, un groupe halo-alcoxycarbonyle en c2-c7, un groupe cyclo-alkyloxycarbonyle en c3-c6, un groupe aralkyloxycarbonyle, un groupe carbamoyl-alcoxy en c1-c6, un groupe carboxy-alkényle en c2-c6 ou un groupe de -q1-n(ra)-q2-rb ; un groupe alkyle en c1-c6, aryle ou hétérocyclique facultativement substitué ; ou un groupe alkyle en c1-c6 ou alkényle en c2-c6 ayant le groupe aryle ou hétérocyclique ; r3 et r4 représentent chacun un atome d'hydrogène, un atome d'halogène, un groupe nitro, un groupe cyclo-alkyle en c3-c6, un groupe carbamoyle facultativement substitué avec un groupe alkyle en c1-c6 ou cyclo-alkyle en c3-c6 ou un groupe de -n(re)rf ; un groupe alcanoyle en c2-c7, alcoxy en c1-c6, alcoxycarbonyle en c2-c7, cyclo-alkyloxycarbonyle en c3-c6, alkylsulfonyle en c1-c6, alkylthio en c1-c6, cyclo-alkyloxy en c3-c6, cyclo-alkyle en c3-c6-alcoxy en c1-c6, cyclo-alkylsulfonyle en c3-c6, cyclo-alkylthio en c3-c6 or cyclo-alkyle en c3-c6 alkylthio-c1-c6 facultativement substitué ; ou un groupe alkyle en c1-c6 facultativement substitué ; t et u représentent chacun un atome d'azote ou un groupe méthine ; et v représente un atome d'oxygène ou un atome de soufre. Le composé de l'invention est utilisable en tant qu'agent thérapeutique pour diverses maladies liées à l'acc.
MA32115A 2006-12-28 2009-07-23 Nouveaux derives d'aminopyrimidine servant d'inhibiteurs de la plk1. MA31109B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2006356575 2006-12-28
JP2007265783 2007-10-11
PCT/JP2007/075240 WO2008081914A1 (fr) 2006-12-28 2007-12-20 Nouveau dérivé d'aminopyrimidine comme inhibiteur de plk1

Publications (1)

Publication Number Publication Date
MA31109B1 true MA31109B1 (fr) 2010-01-04

Family

ID=39588592

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32115A MA31109B1 (fr) 2006-12-28 2009-07-23 Nouveaux derives d'aminopyrimidine servant d'inhibiteurs de la plk1.

Country Status (24)

Country Link
US (1) US7977336B2 (fr)
EP (2) EP2116543A4 (fr)
JP (1) JPWO2008081914A1 (fr)
KR (1) KR101481388B1 (fr)
CN (1) CN101573361B (fr)
AR (1) AR064619A1 (fr)
AU (1) AU2007340530B2 (fr)
BR (1) BRPI0718966B8 (fr)
CA (1) CA2668738A1 (fr)
CL (1) CL2007003758A1 (fr)
CO (1) CO6190523A2 (fr)
CR (1) CR10784A (fr)
EC (1) ECSP099324A (fr)
GT (1) GT200900124A (fr)
IL (1) IL198675A0 (fr)
MA (1) MA31109B1 (fr)
MX (1) MX2009004920A (fr)
NO (1) NO20092770L (fr)
NZ (1) NZ577273A (fr)
PE (1) PE20081845A1 (fr)
RU (1) RU2458062C2 (fr)
SV (1) SV2009003258A (fr)
TW (1) TW200835485A (fr)
WO (2) WO2008081914A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5442449B2 (ja) 2006-12-22 2014-03-12 アステックス、セラピューティックス、リミテッド 新規化合物
EP2114941B1 (fr) 2006-12-22 2015-03-25 Astex Therapeutics Limited Composés hétérocycliques bicycliques servant d'inhibiteurs des fgfr
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
WO2010013633A1 (fr) * 2008-07-31 2010-02-04 萬有製薬株式会社 Procédés de prédiction de l'état rb et de la sensibilité à l'inhibiteur de plk1 d'une cellule
JP4489132B2 (ja) * 2008-08-22 2010-06-23 株式会社東芝 磁気記録媒体の製造方法
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
US8445674B2 (en) 2009-10-21 2013-05-21 Hoffmann-La Roche Inc Heterocyclyl compounds
CA2778949C (fr) 2009-10-30 2018-02-27 Janssen Pharmaceutica Nv Derives d'imidazo[1,2-b]pyridazine et leur utilisation comme inhibiteurs de pde10
UY33213A (es) 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
EP2463289A1 (fr) 2010-11-26 2012-06-13 Almirall, S.A. Dérivés imidazo[1,2-b]pyridazine en tant qu'inhibiteur JAK
BR112013033375B1 (pt) 2011-06-27 2022-05-10 Janssen Pharmaceutica N.V Derivados de 1-aril-4-metil-[1,2,4]triazolo[4,3-a]quinoxa-lina, seu uso, composição farmacêutica que os compreende, processo de preparação dos mesmos, solução estéril e composto intermediário
EP2554544A1 (fr) 2011-08-01 2013-02-06 Almirall, S.A. Dérivés de pyridin-2(1h)-one en tant qu'inhibiteurs de JAK
AU2012313888B2 (en) 2011-09-27 2016-03-31 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
RU2657540C2 (ru) 2012-06-26 2018-06-14 Янссен Фармацевтика Нв Комбинации, содержащие ингибиторы pde 2, такие как 1-арил-4-метил-[1,2,4]триазоло[4,3-а]хиноксалиновые соединения, и ингибиторы pde 10, для применения в лечении неврологических или метаболических расстройств
EP2869822B1 (fr) 2012-07-09 2016-09-14 Janssen Pharmaceutica, N.V. Inhibiteurs de l'enzyme phosphodiestérase 10
EP2879712B1 (fr) 2012-07-31 2018-04-25 Crown Bioscience, Inc. (Taicang) Marqueurs histologiques pour l'identification de patients atteints d'un carcinome du poumon non à petites cellules pour le traitement par un médicament anti-egfr
WO2014046617A1 (fr) * 2012-09-19 2014-03-27 Agency For Science, Technology And Research Compositions et méthodes de traitement du cancer
EP3194367B1 (fr) 2014-09-17 2021-08-18 Boehringer Ingelheim International GmbH Derives de tetrahydrquinoline et compositions pharmaceutiques utiles dans le traitement de l' obesite et du diabete
US20230190717A1 (en) * 2017-04-10 2023-06-22 City Of Hope P38 gamma inhibitors and method of use thereof
CA3146375A1 (fr) * 2019-07-10 2021-01-14 Aucentra Therapeutics Pty Ltd Derives de 4-(imidazo [l, 2-a] pyridine-3-yl)-n-(pyridinyl) pyrimidine-2-amine en tant qu'agents therapeutiques
KR102894509B1 (ko) * 2019-07-24 2025-12-02 메르크 파텐트 게엠베하 4-(이미다조[1,2-a]피리딘-3-일)-피리미딘 유도체
CN112592318B (zh) * 2020-12-12 2022-05-03 贵州医科大学 2-(4-甲氨酰基)苯胺基-4-氨基嘧啶衍生物及应用
JPWO2024071401A1 (fr) 2022-09-29 2024-04-04
CN119318874B (zh) * 2024-12-18 2025-04-15 淄博凯美可工贸有限公司 一种节能型复合脱硫剂的制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5223608A (en) 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
FI95708C (fi) 1988-10-31 1996-03-11 Eisai Co Ltd Analogiamenetelmä 1,4-diatsepiinijohdannaisen ja sen farmaseuttisesti sopivan suolan valmistamiseksi
JPH045029A (ja) 1990-04-23 1992-01-09 Bridgestone Corp 空気入りタイヤ
JP2848958B2 (ja) 1990-09-28 1999-01-20 スミスクライン・ビーチャム・コーポレイション 水溶性カンプトテシン類似体、方法および手段
US5191082A (en) 1990-12-20 1993-03-02 North Carolina State University Camptothecin intermediate and method of making camptothecin intermediates
US5247089A (en) 1990-12-20 1993-09-21 North Carolina State University Method of making intermediates useful for the manufacture of camptothecin and camptothecin analogs
US5162532A (en) 1990-12-20 1992-11-10 North Carolina State University Intermediates and method of making camptothecin and camptothecin analogs
US5243050A (en) 1990-12-20 1993-09-07 North Carolina State University Alkylpyridone DE ring intermediates useful for the manufacture of camptothecin and camptothecin analogs
US5200524A (en) 1990-12-20 1993-04-06 North Carolina State University Camptothecin intermediates and method of making same
DK1975181T3 (da) 1992-10-28 2011-06-06 Genentech Inc Anvendelse af vaskulære endothelcelle-vækstfaktor-antagonister
JP3025602B2 (ja) 1993-05-21 2000-03-27 デビオファーム エス.アー. 光学的に高純度なシス−オキザラート(トランス−l−1,2−シクロヘキサンジアミン)白金(II)錯体の製造方法
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
JPH11507535A (ja) 1995-06-07 1999-07-06 イムクローン システムズ インコーポレイテッド 腫瘍の成長を抑制する抗体および抗体フラグメント類
JP3154399B2 (ja) 1996-07-04 2001-04-09 デビオファーム エス.アー. 白金化合物の製造方法
RU2264403C2 (ru) * 1999-11-10 2005-11-20 Орто-Макнейл Фармасьютикал, Инк. Замещенные 2-арил-3-(гетероарил) имидазо [1,2-а] пиримидины, содержащие их фармацевтические композиции и связанные с ними способы
WO2002046157A2 (fr) 2000-12-04 2002-06-13 Sepracor, Inc. Procedes de synthese stereoselective de piperidines substituees
CA2450555A1 (fr) 2001-06-25 2003-01-03 Merck & Co., Inc. Composes d'heteroaryle fondus (pyrimidyle)(phenyle) substitues inhibiteurs de p38 et de la kinase pkg
AU2002355732B2 (en) 2001-08-01 2006-11-09 Merck Sharp & Dohme Corp. Benzimidazo[4,5-f]isoquinolinone derivatives
UA80296C2 (en) 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
AU2003284399A1 (en) 2002-11-14 2004-06-03 Kyowa Hakko Kogyo Co., Ltd. Plk inhibitors
EP1735319B1 (fr) 2004-03-26 2017-05-03 MethylGene Inc. Inhibiteurs d'histone desacetylase
CA2577947A1 (fr) * 2004-08-31 2006-03-09 Banyu Pharmaceutical Co., Ltd. Nouveaux derives d'imidazoles substitues

Also Published As

Publication number Publication date
JPWO2008081914A1 (ja) 2010-04-30
NO20092770L (no) 2009-09-25
RU2009128966A (ru) 2011-02-10
AU2007340530A1 (en) 2008-07-10
TW200835485A (en) 2008-09-01
CN101573361B (zh) 2012-05-30
CL2007003758A1 (es) 2008-07-04
KR101481388B1 (ko) 2015-01-12
CN101573361A (zh) 2009-11-04
IL198675A0 (en) 2010-02-17
CO6190523A2 (es) 2010-08-19
BRPI0718966A2 (pt) 2014-01-07
RU2458062C2 (ru) 2012-08-10
EP2114942B1 (fr) 2012-10-31
US7977336B2 (en) 2011-07-12
BRPI0718966B8 (pt) 2021-05-25
PE20081845A1 (es) 2008-12-27
US20080305081A1 (en) 2008-12-11
EP2116543A4 (fr) 2010-09-08
MX2009004920A (es) 2009-05-21
EP2114942A4 (fr) 2010-09-08
EP2116543A1 (fr) 2009-11-11
BRPI0718966B1 (pt) 2020-11-17
KR20090092822A (ko) 2009-09-01
ECSP099324A (es) 2009-06-30
GT200900124A (es) 2010-11-03
CR10784A (es) 2009-09-16
CA2668738A1 (fr) 2008-07-10
WO2008081910A1 (fr) 2008-07-10
AU2007340530B2 (en) 2012-09-13
WO2008081914A1 (fr) 2008-07-10
AR064619A1 (es) 2009-04-15
SV2009003258A (es) 2010-08-23
NZ577273A (en) 2011-03-31
EP2114942A1 (fr) 2009-11-11

Similar Documents

Publication Publication Date Title
MA31108B1 (fr) Derives substitues de spirochromanone en tant qu'inhibiteurs d'acc
WO2008088692A3 (fr) Dérivés spirochromanone
Ravi et al. N-chlorosuccinimide-promoted regioselective sulfenylation of imidazoheterocycles at room temperature
Bregman et al. Discovery of novel, induced-pocket binding oxazolidinones as potent, selective, and orally bioavailable tankyrase inhibitors
Manetti et al. Identification of a novel pyrazolo [3, 4-d] pyrimidine able to inhibit cell proliferation of a human osteogenic sarcoma in vitro and in a xenograft model in mice
Fei et al. New substituted benzimidazole derivatives: a patent review (2010–2012)
CA3015271C (fr) Derives de dioxyde d'iminothiadiazinane utilises comme inhibiteurs de la plasmepsine v
ZA200500022B (en) 1-(Aminoalkyl)-3-sulfonylazaindoles as 5-hydroxytryptamine-6 ligans
TW200413379A (en) Fused azole-pyrimidine derivatives
PT97960A (pt) Processo de oxidacao de arilsulfetos a arilsulfoxidos
AU2018326721A1 (en) Compounds and compositions for IRE1 inhibition
Tiwari et al. Copper-catalyzed synthesis of benzoxazoles via tandem cyclization of 2-halophenols with amidines
Liu et al. Potent, non-covalent reversible BTK inhibitors with 8-amino-imidazo [1, 5-a] pyrazine core featuring 3-position bicyclic ring substitutes
Zeng et al. Discovery of potent dipeptidyl peptidase IV inhibitors through pharmacophore hybridization and hit-to-lead optimization
Jiang et al. Regio-and diastereoselective synthesis of 3, 4-dihydro-2H-benzo [4, 5] imidazo [2, 1-b][1, 3] thiazine derivatives via DBU-catalyzed [3+ 3] annulation of MBH carbonates with 2-mercaptobenzimidazoles
EP3091982A1 (fr) Composés organiques
AR036735A1 (es) Derivados de 5-metoxi-8-aril-[1,2,4]triazolo[1,5-a]piridina
Leca et al. Acid-Catalyzed Aza-Diels− Alder Reactions for the Total Synthesis of (±)-Lapatin B
Badrey et al. An approach to polysubstituted triazipines, thiadiazoles and thiazoles based on benzopyran moiety through the utility of versatile hydrazonoyl halides as in vitro monoamine oxidase inhibitors
Lauria et al. Pyrazolo [3, 4-d][1, 2, 3] triazolo [1, 5-a] pyrimidine: a new ring system through Dimroth rearrangement
CA3142435A1 (fr) Derives de 3-(2- (heteroaryl)-pyridin-4-yl)-5-(trifluoromethyl) -1,2,4-oxadiazole utilises en tant qu'inhibiteurs de hdac6
BR0307008A (pt) N-aril-4,5-dia-minopirazóis e agentes de tingimento que contêm esses compostos
Zheng et al. Design and synthesis of a tetracyclic pyrimidine-fused benzodiazepine library
Lotfata et al. A Simple and Efficient Regioselective and Chemoselective Synthesis of New Substituted 3‐Methyl‐6‐arylpyridazine‐4‐carboxamides and 5‐Oxo‐3‐aryl‐5, 6‐dihydropyrido [4, 3‐c] pyridazine‐8‐carbaldehydes
ZA200505036B (en) Diamine deivatives